Meet Divyam, a 26-year-old with moderate plaque PsO.1
‘My job takes me all over the country and it is important that I make a good first impression. A psoriasis flare is the last thing I need as people think I have got an infectious disease’.2
‘The lesions come and go,3,4 and if I knew when they would appear, it would make my life easier. I have been prescribed PUVA and ciclosporin, but they are not always effective. So, I generally cover up when I meet new people’.
The course and progress of PsO is unpredictable3,4
Note: This is a hypothetical case for representation purpose only.
Patients with PsO such as Divyam whose symptoms have cyclical benefit from individualised treatment with Enbrel®5-9
From CRYSTEL, a randomised, open-label study that compared continuous and intermittent Enbrel® dosing regimens in 720 patients with PsO.5,*
PASI Improvement Over 54 Weeks5
P<0.01 for both groups versus baseline from Week 3 onwards.
Adapted from Ortonne JP, et al. 2008.
Please consult the LPD for contraindications, warnings, precautions and other important safety information.
Please note: The examples described here are not of actual patients, but fictitious representations of scenarios for which Enbrel® (etanercept) could be considered.
*From CRYSTEL, a randomised, open-label, multicentre study of 720 patients with PsO treated (1:1) with continuous or intermittent Enbrel®.5 From Weeks 3 to 54, both dose regimens significantly improved PGA and PASI scores versus baseline.5,8 Significant improvements were also observed across a range of PROs, including DLQI, EQ-5D, HADS-D, HADS-A and SF-36 Vitality.6
Study design: Ortonne JP, et al. 2008.
In CRYSTEL, the continuous therapy group received Enbrel® 25 mg BIW throughout the 54-week study. The intermittent therapy group received Enbrel® 50 mg BIW for up to 12 weeks. Therapy was temporarily paused during that time when a target response (PGA ≤2) was achieved. When a patient subsequently relapsed (PGA ≥3), Enbrel® (25 mg BIW for up to 24 weeks) was re-initiated until the target response was regained. Patients who failed to achieve the initial target response by Week 12, but whose PGA score improved by at least 1 unit, continued treatment with Enbrel® 25 mg BIW for up to 24 weeks or until the target response was reached. In both treatment groups, patients who did not show improvement of at least 1 unit from baseline PGA by Week 12 were considered treatment failures, and were discontinued from the study.5
The trial’s primary endpoint was mean PGA over 54 weeks. Secondary endpoints included changes from baseline in mean PGA and PASI, and patient satisfaction with current PsO treatment.5
PROs evaluated included DLQI, EQ-5D, HADS and the SF-36 Vitality subscale.6
†From a 72-week, long-term extension study. In total, 912 patients with PsO received 50 mg Enbrel® QW for 12 weeks; thereafter, patients could maintain 50 mg QW (n=321) or escalate to 50 mg BIW (n=591) based on 1 of 3 predetermined criteria. Patients had experienced an interruption in Enbrel® treatment between the last dose of the parent Phase 3 study and the first dose of this extension study, and comparisons were made between those with treatment gaps of ≤30 versus >30 days.9
BIW, twice a week; DLQI, Dermatology Life Quality Index; CRYSTEL, Clinical Randomized Year-long Study assessing the safety and efficacy of EnbreL in psoriasis; EQ-5D, EuroQoL-5D; HADS-A, Hospital Anxiety and Depression Scale-Anxiety; HADS-D, Hospital Anxiety and Depression Scale-Depression; PASI, Psoriasis Area and Severity Index; PGA, physician global assessment; PRO, patient-reported outcome; PsO, psoriasis; PUVA, psoralen plus ultraviolet A radiation; QW, once a week; SF-36, Short Form-36; SmPC, summary of product characteristics.
Please click the Prescribing Information link to view the safety and adverse events information of Enbrel®.
For the use only of Registered Medical Practitioners or a Hospital or a Laboratory.
PP-ENB-IND-0814 August 2022
These pages are not intended for patients or for members of the general public. The web pages contain promotional content.
If you select 'No', you will be redirected to Pfizer.co.in
For more details on, Who is a Registered medical practitioner*, please visit https://cdsco.gov.in/opencms/export/sites/CDSCO_WEB/Pdf-documents/acts_rules/2016DrugsandCosmeticsAct1940Rules1945.pdf , Page No. 39, Rule 2 part (ee), last accessed on 26th April 2021.
Address: The Capital, A Wing, 1802, 18th Floor, Plot No. C-70, 'G' Block, Bandra Kurla Complex, Bandra East, Mumbai - 400051.